My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer - Episode 6

Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA

,

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer
    EP. 2: Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
    EP. 3: Evolving Treatment Paradigm and NCCN Guideline Updates
    EP. 4: The EMBARK trial investigating enzalutamide in NM CSPC
    EP. 5: The Role of PSA Doubling Time in Risk Assessment
    Now Viewing
    EP. 6: Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
    EP. 7: Patient Case 2: Metastatic CSPC
    EP. 8: Final Thoughts on CSPC
    1. Efstathiou: What are your impressions of the patient case? How would you evaluate and risk stratify this patient?
    x